What Core Diagnostics does

Core Diagnostics is a Gurugram-based Clinical Data Science company operating a high-end diagnostic laboratory platform in India. It serves oncologists, hematologists, gynecologists, cardiologists, and other specialists across 9 specialty areas (onCORE, hemaCORE, reproCORE, cardioCORE, endoCORE, nephroCORE, uroCORE, eyeCORE, neuroCORE) using molecular diagnostics, next-generation sequencing, liquid biopsy (52-gene liquiCORE panel), flow cytometry, immunohistochemistry (150+ markers via dualCORE), histopathology, cytogenetics, and telepathology. The company is CAP and NABL accredited, operates a hub-and-spoke network of one reference laboratory in Gurugram and six regional reference labs, and supports companion diagnostics for pharmaceutical companies.

The company monetizes through a hybrid model: one-time test fees across a premium menu (₹1,200–₹48,000 per test), subscription-based chronic disease management plans in partnership with CIPRA.ai (₹10,000–₹27,500), pharma clinical trial and companion diagnostic services, outsourced lab management for partner facilities, and the COREcertify professional education program. Distribution is omnichannel — direct B2C via website and call centre, B2B through hospitals and doctors, partner collection centres nationwide, and home collection services. Recent strategic moves include consolidation of its genomics lab into Metropolis Healthcare's Centre of Genomics (January 2026), an academic MoU with SRMIST (February 2026), and a multi-cancer screening collaboration with PredOmix (July 2023).

Name

Core Diagnostics

Legal name

Core Diagnostics Private Limited

Website

https://corediagnostics.in

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Core Diagnostics is a Gurugram-based high-end clinical laboratory offering advanced molecular, genomic, and immunohistochemistry diagnostics across oncology, hematology, and chronic disease specialties, serving doctors, hospitals, pharma, and patients across India via seven labs and home collection.

Ownership category

akta.pro rank

Product category

Clinical Diagnostic Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Reference & Esoteric Testing Laboratories (HLAFAMAJ)

akta.pro secondary industries

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Clinical Research & Trial Central Laboratories (HLAFAMAL)

Keywords

• Clinical diagnostic services
• Molecular diagnostics
• Next generation sequencing
• Immunohistochemistry panels
• Liquid biopsy testing

Headquarters

HQ city

Gurugram

HQ country

India

HQ region

Asia

Offices17 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Clinical Laboratory Testing Services: One-time diagnostic test fees covering comprehensive panels across oncology, hematology, cardiology, nephrology, reproductive health, endocrinology, and neurology. Tests include molecular diagnostics, NGS panels, immunohistochemistry, flow cytometry, histopathology, cytopathology, and cytogenetics. Revenue recognized upon test completion and report delivery within 2-14 days.
2. Chronic Disease Subscription Plans: Recurring subscription plans for AI-powered chronic disease management (Diabetes and Hypertension) combining CIPRA.ai app with periodic diagnostic monitoring tests. Plans offered as 6-month and 12-month subscriptions with bundled diagnostic tests at defined intervals.
3. Pharma Programs & Clinical Trial Services: B2B revenue from pharma companies for clinical trial support, companion diagnostic development, and data services. The company positions itself as a bioinformatics partner for pharma's data-driven future in healthcare.
4. Lab Management Services: Outsourced lab management services where Core Diagnostics manages capital, skills, and management bandwidth for partner labs, focusing on patient care operations.
5. COREcertify Education Programs: Professional education and certification programs for lab professionals covering latest testing methods and technologies in Histopathology, Immunohistochemistry, Cytology, Hematology & Molecular Genetics.

Pricing tiers

Go-to-market motion2 records

Distribution channels7 records

Marketing channels6 records

Core offering

Core Diagnostics is a high-end clinical laboratory providing advanced molecular diagnostics, next-generation sequencing (NGS), liquid biopsy, immunohistochemistry (IHC), flow cytometry, histopathology, cytogenetics, and companion diagnostic services across 9 specialty areas. The company delivers diagnostic test reports (turnaround 2-14 days) to referring physicians, hospitals, and directly to patients, while also offering B2B services including pharma clinical trial support and lab management for partner facilities.

Product overview

Core Diagnostics is a Clinical Data Science company with a Center-of-Excellence in High End Diagnostics, integrating Data Scientists, Lab Technicians, Pathologists, and AI Systems. The company operates a portfolio of nine CORE-branded diagnostic specialty panels: onCORE (hereditary and sporadic cancers), hemaCORE (hematological disorders), reproCORE (reproductive health), cardioCORE (cardiovascular diseases), endoCORE (endocrine disorders), nephroCORE (kidney diseases), uroCORE (urological disorders), eyeCORE (ophthalmologic conditions), and neuroCORE (brain and nervous system disorders). Complementing these, the company offers advanced targeted panels including dualCORE (150+ IHC markers for poorly differentiated tumors), liquiCORE (liquid biopsy panels for 52 genes and lung cancer), geneCORE Somatic, pulmoCORE, coloCORE, mammaCORE, and the Comprehensive Hematological Malignancy Panel. An integrated AI capability is provided through CIPRA.ai, a chronic disease management and reversal program using Digital Twin technology for personalized Diabetes and Hypertension care. Routine testing, subscription health plans, and home collection services round out the offering. The platform is supported by NABL and CAP accredited laboratories including a reference lab in Gurugram and six regional reference laboratories.

Differentiator

Problem solved

Functional benefit

Products and services

• onCORE
• hemaCORE Diagnostic solutions for multiple hematological disorders including leukemia, lymphoma, and myeloproliferative neoplasms, utilizing flow cytometry, molecular genetics, and cytogenetics. For hematologists and bone marrow transplant centers.
• reproCORE Reproductive health diagnostic solutions encompassing infertility testing, prenatal screening, pregnancy monitoring, and sexual health diagnostics. For gynecologists, reproductive medicine specialists, and patients.
• cardioCORE Genetic tests for cardiovascular diseases and non-invasive tests for heart blockage, supporting cardiac risk assessment and management. For cardiologists and patients with cardiac risk.
• endoCORE Diagnosis of genetic endocrine disorders across a range of symptoms and severity levels, supporting endocrine disease stratification. For endocrinologists and patients.
• nephroCORE Kidney disease diagnosis at an earlier stage than current diagnostic solutions, covering glomerular, tubular, and hereditary renal conditions. For nephrologists.
• uroCORE Detection of urological disorders affecting the urinary tract, bladder, and prostate through specialized molecular and histopathological testing. For urologists.
• eyeCORE Specialized ophthalmologic testing for genetic and molecular eye disorders, supporting diagnosis of hereditary ocular conditions. For ophthalmologists.
• neuroCORE Genetic testing and counselling for diagnosis of brain and nervous system disorders, covering neuro-oncology, neurodegenerative, and neurodevelopmental conditions. For neurologists.
• dualCORE Advanced immunohistochemistry panel using esoteric lineage-specific and lineage-associated markers for the differential diagnostic work-up of poorly differentiated tumors, carcinomas of unknown primary, soft tissue sarcomas, hematolymphoid neoplasms, and neuroendocrine tumors. Features 150+ IHC markers. For oncologists and pathologists.
• liquiCORE 52 Gene Panel Comprehensive liquid biopsy panel analyzing 52 genes for hotspot SNVs, short indels, gene fusions, copy number variations, and tumor suppressor genes across multiple cancer types from blood samples. For oncologists when tissue is unavailable.
• geneCORE Somatic 52 Gene Panel Somatic gene panel covering 52 genes for hotspot mutations, gene fusions, and copy number variations to support oncology treatment selection and disease profiling in solid tumors. For oncologists.
• pulmoCORE 20 Gene Panel Pulmonary oncology panel targeting 20 genes for hotspot SNVs, gene fusions, and copy number variations in lung cancer, covering actionable targets including EGFR, ALK, ROS1, BRAF, KRAS, and NTRK. For pulmonologists and oncologists.
• coloCORE Targeted Panel-1 Colorectal cancer targeted panel covering TP53, KRAS, NRAS, BRAF, ERBB2, NTRK1/2/3, PIK3CA with MSI-PCR testing for colorectal cancer molecular profiling. For oncologists.
• mammaCORE Panel 1 Breast cancer panel assessing ER, PR, and HER2/neu status for breast cancer diagnosis and treatment planning. For oncologists and breast surgeons.
• Comprehensive Hematological Malignancy Panel Broad hematology panel covering hotspot genes, full genes, gene fusions, and expression genes for comprehensive hematological malignancy profiling, including B-ALL MRD detection. For hematologists.
• BCR-ABL Quantitative International Scale Quantitative BCR-ABL molecular test on the International Scale for monitoring chronic myeloid leukemia treatment response and minimal residual disease. For hematologists.
• BRCA 1 and 2 Gene Sequencing Panel Germline genetic testing panel for BRCA1 and BRCA2 gene sequencing to assess hereditary breast and ovarian cancer risk and guide PARP inhibitor therapy selection. For oncologists, genetic counselors, and patients.
• Multiple Myeloma Diagnostic Panel Comprehensive diagnostic panel for multiple myeloma including serum protein electrophoresis, immunofixation, free light chains, beta-2 microglobulin, and routine chemistry for diagnosis and monitoring. For hematologists.
• Pre Operative Profile Routine preoperative blood test panel covering CBC, blood group, glucose, kidney function, coagulation studies, and infectious disease screening (HIV, HBsAg, HCV) for surgical preparation. For surgeons and patients.
• Women Infertility Panel Hormonal panel for female infertility assessment covering TSH, prolactin, and AMH for evaluation of ovarian reserve and reproductive health. For gynecologists and patients.
• Male Infertility Panel Hormonal assessment panel for male infertility including testosterone total, FSH, and LH for evaluating male reproductive function. For andrologists and patients.
• Karyotyping for Genetic Disorders Chromosomal karyotype analysis for detecting numerical and structural chromosomal abnormalities in genetic disorders, infertility, and prenatal cases. For geneticists and reproductive medicine specialists.
• Anti Nuclear Antibody (ANA/ANF) IFA Immunofluorescence assay for antinuclear antibodies using HEp-2 cells as a screening test for autoimmune connective tissue diseases including SLE. For rheumatologists.
• Ph-like ALL Panel Philadelphia chromosome-like acute lymphoblastic leukemia (BCR-ABL1-like ALL) diagnostic panel for high-risk subtype identification and tyrosine kinase inhibitor treatment decisions, recommended by NCCN. For hematologists.
• Histopathology Kidney Biopsy Panel (LM+IF) Combined light microscopy and immunofluorescence analysis of kidney biopsy specimens for diagnosis of glomerular and renal parenchymal diseases. For nephropathologists and nephrologists.
• CIPRA Chronic Disease Management & Reversal Program AI-powered chronic disease management subscription program in partnership with CIPRA.ai, utilizing Digital Twin technology to provide personalized, precise monitoring and lifestyle recommendations for Type 2 Diabetes and Hypertension management and reversal. Includes scheduled diagnostic monitoring tests. For chronic disease patients.
• Home Collection Service At-home sample collection service with trained service executives using specialized collection kits, covering samples from doorstep to the main laboratory. Available across India including 12 countries. For patients preferring at-home sample collection.
• liquiCORE Lung Panel Liquid biopsy panel targeting lung cancer-specific biomarkers including hotspot SNVs for ALK, BRAF, EGFR, KRAS, MET, NRAS, PIK3CA, ROS1, TP53, gene fusions, MET exon 14 skipping, and MET copy number variation. For oncologists managing lung cancer patients.
• ALL Multiplex Basic Multiplex PCR panel for detecting key fusions in acute lymphoblastic leukemia including BCR-ABL, MLL-AF9, MLL-AF4, MLL-EN6, t(1;19), and t(12;21). For hematologists.
• B2B Lab Management Services Outsourced lab management services where Core Diagnostics manages capital, skills, and management bandwidth for partner diagnostic labs, focusing on patient care operations and accreditation support. For partner diagnostic laboratories and hospital pathology departments.
• COREcertify Education Programs Professional education and certification programs for lab professionals covering latest testing methods and technologies in Histopathology, Immunohistochemistry, Cytology, Hematology & Molecular Genetics. For lab professionals and pathologists.

Quantifiable outcome

• Illumina NovaSeq X Series infrastructure enables high-throughput, high-quality genomic sequencing at scale
• +1 more outcomes

Named customers6 records

Segments7 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature9 records

Partnerships

Three partnerships are on record, tiered core and flagship.

• SRM Institute of Science and Technology (SRMIST)coreStrategic or Co-development Partner · 23 February 2026MoU signed to bridge academic learning and real-world oncology practice. Provides SRMIST students hands-on exposure to next-generation sequencing, genetic counselling frameworks, and industry-led research. Opens avenues for joint research initiatives aimed at advancing cancer diagnostics and improving patient outcomes.
• Metropolis HealthcareflagshipStrategic or Co-development Partner · 13 January 2026Core Diagnostics' specialized genomics laboratory in Delhi NCR is integrated into Metropolis Healthcare's Centre of Genomics, which consolidates and scales capabilities in advanced genomics, molecular diagnostics, precision medicine, and genomic research across India. The Centre unifies Metropolis's Global Reference Laboratory in Mumbai with Core Diagnostics' specialized genomics lab in Delhi NCR, operating as CAP-accredited national referral laboratories powered by Illumina NovaSeq X Series.
• CIPRA.aicoreStrategic or Co-development PartnerPartnership to launch AI-powered chronic disease management platform combining CIPRA.ai's AI digital twin technology with Core Diagnostics' periodic diagnostic monitoring tests for Diabetes and Hypertension management and reversal.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• MedGenome: India- and US-based genomics and molecular diagnostics company focused on NGS-based hereditary and oncology testing. Most direct competitor to Core Diagnostics on liquid biopsy, NGS panels, and rare-disease genomics, serving similar oncologist and hospital segments.
• Metropolis Healthcare: Pan-India listed diagnostics chain with broad test menu including molecular diagnostics and genomics. Strategic partner that consolidated Core's genomics lab into its Centre of Genomics (Jan 2026), directly comparable on specialty testing, B2B hospital network, and accreditation standards.
• Thyrocare Technologies: Listed Indian diagnostic chain specializing in high-volume preventive and routine pathology. Comparable to Core on test-menu breadth and pan-India reach but operates at substantially lower price points and broader, less-specialized focus.
• Neuberg Diagnostics: India-based multi-specialty diagnostic chain with strong presence in southern India and growing international footprint. Comparable to Core Diagnostics on advanced molecular testing, hospital partnerships, and integrated reference-lab model.
• Dr. Lal PathLabs: India's largest listed diagnostic chain by revenue and network, offering routine and specialized pathology nationwide. Comparable to Core Diagnostics on consumer testing, hospital B2B contracts, and NABL accreditation; differs through far greater scale and brand reach.
• Agilus Diagnostics (formerly SRL Diagnostics): Major pan-India diagnostic chain with extensive specialty and reference lab capabilities, part of the Fortis/Manipal group. Comparable on hospital B2B pathology, oncology panels, and reference-lab accreditation; larger footprint and corporate backing distinguish it from Core.

Emerging players

• Guardant Health: US-based liquid biopsy specialist offering Guardant360 comprehensive genomic profiling; listed technology partner of Core Diagnostics. Comparable on liquid biopsy assays, oncology companion diagnostics, and pharma partnerships; global leader in circulating tumor DNA testing.
• Strand Life Sciences: India-based genomics and bioinformatics company focused on NGS, hereditary cancer testing, and clinical genomic interpretation. Closely comparable to Core's bioinformatics-driven specialty testing strategy, though smaller in consumer-facing scale.

Broad incumbents

• Foundation Medicine: US-based molecular diagnostics leader (Roche subsidiary) specializing in comprehensive genomic profiling for oncology. Comparable to Core on liquid biopsy and comprehensive genomic panels; a benchmark for the global premium molecular diagnostics category Core aspires to compete in internationally.
• Caris Life Sciences: US-based molecular diagnostics and precision medicine company offering comprehensive tumor profiling (MI Profile), liquid biopsy, and AI-driven analytics. Comparable to Core Diagnostics on oncology molecular profiling and companion diagnostic development; substantially larger scale.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/corediagnostics
• Facebookfacebook.com/corediagnostics
• LinkedInlinkedin.com/company/core-diagnostics

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds3 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Core Diagnostics